ESR1 and breast carcinoma: In patients with breast cancer, the comparison of immunohistochemical results between primary and metastatic lesions revealed that ER levels decreased slightly after endocrine therapy, while PR levels decreased dramatically, with up to half of the tumors completely losing PR expression with the development of drug resistance (21).